{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARSI",
    "query": {
      "intervention": "ARSI"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ARSI&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T02:51:14.042Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06141993",
      "title": "ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Prostate Cancer",
        "Prostate Adenocarcinoma",
        "Prostate Cancer Metastatic",
        "Castration-resistant Prostate Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2024-05-13",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 3,
      "location_summary": "New York, New York • Durham, North Carolina • Madison, Wisconsin",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06141993"
    },
    {
      "nct_id": "NCT04279561",
      "title": "Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8",
        "Stage IVA Prostate Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Gallium Ga 68 Gozetotide",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 9,
      "start_date": "2020-04-16",
      "completion_date": "2022-09-15",
      "has_results": false,
      "last_update_posted_date": "2022-09-21",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04279561"
    },
    {
      "nct_id": "NCT05612880",
      "title": "Physical Function During ARSI Treatment",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Advanced Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "androgen receptor signaling inhibitors",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2022-10-13",
      "completion_date": "2024-11-06",
      "has_results": false,
      "last_update_posted_date": "2025-01-09",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05612880"
    },
    {
      "nct_id": "NCT06734130",
      "title": "Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration Sensitive Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Luteinizing Hormone-Releasing Hormone (LHRH) analog",
          "type": "DRUG"
        },
        {
          "name": "Androgen Receptor Signal Inhibitor (ARSI)",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 25,
      "start_date": "2025-01-10",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06734130"
    },
    {
      "nct_id": "NCT06150417",
      "title": "MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Malignant Neoplasm of Prostate",
        "Secondary Malignant Neoplasm of Prostate"
      ],
      "interventions": [
        {
          "name": "Androgen deprivation therapy (ADT)",
          "type": "DRUG"
        },
        {
          "name": "Androgen receptor signaling inhibitor (ARSI)",
          "type": "DRUG"
        },
        {
          "name": "Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)",
          "type": "OTHER"
        },
        {
          "name": "Metastasis directed radiotherapy (MDRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 200,
      "start_date": "2024-07-01",
      "completion_date": "2028-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 3,
      "location_summary": "New York, New York • Cleveland, Ohio • Madison, Wisconsin",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06150417"
    },
    {
      "nct_id": "NCT06429813",
      "title": "Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Castrate Sensitive Prostate Cancer",
        "Metastatic Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Home-Based Exercise Intervention - Walking",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Home-Based Exercise Intervention - HIIT Cycling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Paul Viscuse",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2024-07-26",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06429813"
    },
    {
      "nct_id": "NCT07210086",
      "title": "Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ADT",
          "type": "DRUG"
        },
        {
          "name": "ARSI",
          "type": "DRUG"
        },
        {
          "name": "No ADT/ARSI -decline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2025-11-26",
      "completion_date": "2028-05-13",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07210086"
    },
    {
      "nct_id": "NCT05997615",
      "title": "Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hormone-refractory Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "VIR-5500",
          "type": "DRUG"
        },
        {
          "name": "Androgen receptor signaling inhibitor (ARSI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 437,
      "start_date": "2023-08-10",
      "completion_date": "2027-09-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Houston, Texas • Fairfax, Virginia + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05997615"
    },
    {
      "nct_id": "NCT06844383",
      "title": "A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer (Adenocarcinoma)",
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)"
      ],
      "interventions": [
        {
          "name": "Talazoparib with enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prostate Cancer Clinical Trials Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 126,
      "start_date": "2026-05-04",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 8,
      "location_summary": "Duarte, California • La Jolla, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06844383"
    },
    {
      "nct_id": "NCT03725761",
      "title": "Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 31,
      "start_date": "2018-10-24",
      "completion_date": "2027-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-09-03T02:51:14.042Z",
      "location_count": 3,
      "location_summary": "New York, New York • Madison, Wisconsin",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03725761"
    }
  ]
}